Trial of Ruxolitinib and Erlotinib in Patients With EGFR-mutant Lung Adenocarcinoma With Acquired Resistance to Erlotinib
Clinical trial NCT02155465 · COMPLETED
Trial details
- NCT number
- NCT02155465
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Status
- COMPLETED
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2014-06-01
- Primary completion
- 2017-10-01
- Enrollment
- 22
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.